Review
Published on 26 Oct 2023
PARP inhibitors combined with radiotherapy: are we ready?
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1234973
- 4,866 views
- 7 citations
121 articles related to "Parp Inhibitors"
Articles
Review
Published on 04 Dec 2023
Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization
in Radiation Oncology
Frontiers in Oncology
doi 10.3389/fonc.2023.1295579
- 1,240 views
Review
Published on 20 Dec 2013
Structural Implications for Selective Targeting of PARPs
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2013.00301
- 17,531 views
- 132 citations
Systematic Review
Published on 03 Jul 2020
Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
in Women's Cancer
Frontiers in Oncology
doi 10.3389/fonc.2020.00954
- 5,446 views
- 12 citations
Original Research
Published on 15 Jun 2022
Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2022.912256
- 11,233 views
- 16 citations
Review
Published on 06 Jul 2022
Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.939570
- 8,927 views
- 11 citations
Original Research
Published on 14 Feb 2024
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway
in Gynecological Oncology
Frontiers in Oncology
doi 10.3389/fonc.2024.1302850
- 1,860 views
Review
Published on 03 Mar 2020
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2020.00170
- 19,725 views
- 66 citations
Review
Published on 24 Apr 2023
PARP inhibitors in metastatic prostate cancer
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2023.1159557
- 12,695 views
- 26 citations
Review
Published on 01 Oct 2013
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2013.00237
- 17,956 views
- 52 citations
Review
Published on 25 Nov 2021
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
in Breast Cancer
Frontiers in Oncology
doi 10.3389/fonc.2021.769280
- 18,425 views
- 55 citations
Review
Published on 03 Oct 2022
Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2022.965244
- 7,689 views
- 9 citations
Review
Published on 05 May 2021
Targeting Parthanatos in Ischemic Stroke
in Stroke
Frontiers in Neurology
doi 10.3389/fneur.2021.662034
- 11,639 views
- 37 citations
Review
Published on 07 Feb 2020
PARP Inhibitors in Prostate and Urothelial Cancers
in Genitourinary Oncology
Frontiers in Oncology
doi 10.3389/fonc.2020.00114
- 8,977 views
- 14 citations
Systematic Review
Published on 16 Jun 2020
Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
in Women's Cancer
Frontiers in Oncology
doi 10.3389/fonc.2020.00958
- 9,360 views
- 14 citations
Case Report
Published on 05 May 2023
Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
in Breast Cancer
Frontiers in Oncology
doi 10.3389/fonc.2023.1158981
- 2,256 views